Welcome to our dedicated page for TransMedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TransMedics Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TransMedics Group's regulatory disclosures and financial reporting.
TransMedics Group, Inc. director James R. Tobin reported a bona fide gift transfer of 18,000 shares of common stock on 2026-08-17 from an indirect holding titled "The Tobin 2024 Family Trust," leaving that trust with 0 shares. Following this reporting, Tobin holds 6,981 shares of TransMedics common stock directly and 155,146 shares indirectly through the "James R. Tobin 2012 Trust."
TransMedics Group reported financial results for the quarter ended June 30, 2026. Total revenue was $189.9 million, a 21% increase from $157.4 million in the prior-year quarter, driven by higher utilization of the Organ Care System in liver and heart through the National OCS Program and growth in logistics services. Product revenue was $111.2 million and service revenue was $78.8 million. Net income was $14.7 million, or $0.41 per diluted share, compared with $34.9 million, or $0.92 per diluted share, a year earlier. Adjusted net income was $16.2 million, or $0.44 per diluted share.
Gross margin was 60% versus 61% a year ago. Operating expenses rose to $89.5 million from $60.0 million, reflecting investment in OCS Kidney, next-generation OCS 3.0, clinical programs and infrastructure. Income from operations declined to $23.7 million, for a 12.5% operating margin, compared with $36.6 million and a 23.2% margin in the prior-year quarter. Cash totaled $472.7 million as of June 30, 2026. Management raised the low end of full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth versus the prior year and excluding revenue from the strategic investment in PAD Aviation completed on July 1, 2026.
TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards. He received 11,727 restricted stock units (RSUs), each representing a contingent right to one share of common stock, bringing his direct common stock holdings to 41,558 shares.
He was also granted a stock option for 17,784 shares of common stock at an exercise price of $71.23 per share, expiring on July 10, 2036. The option vests at 2.0833% per month starting after April 10, 2026 and is scheduled to be fully vested by April 10, 2030, subject to continued service.
Hernandez Gerardo reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. Chief Financial Officer Gerardo Hernandez received equity awards on 2026-07-10 consisting of 17,246 RSUs, each representing one share of common stock, and stock options for 26,153 shares at $71.23 per share, vesting monthly from April 10, 2026 through April 10, 2030. Following these grants, he holds 31,935 common shares directly and 26,153 options expiring July 10, 2036.
Hassanein Waleed H reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group President & CEO Waleed H. Hassanein received equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at $71.23 per share, vesting monthly from April 2026 to April 2030.
Following these awards, he holds 171,093 shares directly and options on 112,984 shares, plus indirect holdings of 150,000 shares through the Hassanein 2026 Qualified Annuity Trust and 345,009 shares through the Waleed H. Hassanein Revocable Trust; a 150,000‑share transfer between these trusts was a change in the form of beneficial ownership exempt under Rule 16a-13.
TransMedics Group director Thomas J. Gunderson exercised stock options to acquire 19,285 shares of common stock at an exercise price of $2.21 per share on June 15, 2026. On the same date he sold 9,624 shares at $75.06 per share, and after these transactions he directly holds 16,642 common shares. A contextual note states that shares sold were used to cover the option exercise price and related tax withholding obligations.
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Stephanie Lovell received an equity award in the form of restricted stock units. On May 20, 2026, she was granted 2,922 shares of common stock at a price of $0.00 per share as a compensation-related award, not an open-market purchase. Each restricted stock unit represents a contingent right to receive one share of TransMedics common stock. Following this grant, Lovell directly holds 5,788 shares of the company’s common stock.
Weill David reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director David Weill reported an equity compensation grant of 2,922 shares of common stock in the form of restricted stock units. Each RSU represents a contingent right to receive one share of common stock, with no cash paid per share. Following this award, Weill directly holds 15,056 shares of TransMedics common stock, reflecting a routine compensation-related increase in his ownership rather than an open-market purchase.